Cynaropicrin / BAX Cancer Research Results

Cynaropicrin (CYN) — a guaianolide sesquiterpene lactone and major bitter bioactive constituent of Cynara cardunculus / globe artichoke, particularly artichoke leaves. Major reported cancer-relevant effects include apoptosis induction, proliferation inhibition, cell-cycle disruption, tubulin/c-Myc signaling interference, and suppression of inflammatory and survival pathways including NF-κB and JAK/STAT signaling. Clinical anticancer efficacy has not been established; evidence remains predominantly preclinical.

Cynaropicrin — a naturally occurring guaianolide-type sesquiterpene lactone and electrophilic bitter phytochemical found particularly in the leaves of Cynara cardunculus / Cynara scolymus (artichoke). It is formally classified as a plant-derived sesquiterpene lactone. Its α-methylene-γ-lactone and related α,β-unsaturated carbonyl functionality can act as Michael acceptors toward cellular thiols, providing a plausible chemical basis for glutathione depletion, thiol-protein modification, oxidative stress, and inhibition of redox-sensitive signaling proteins. Cancer studies indicate substantial mechanistic heterogeneity, with ROS-dependent mitochondrial injury, STAT3/c-Myc signaling suppression, apoptosis, parthanatos, paraptosis-like death, and context-dependent autophagy/mitophagy among the best-supported effects. Cynaropicrin is not an approved anticancer drug.

Primary mechanisms (ranked):

1. Electrophilic thiol reactivity with GSH/thioredoxin systems → redox disruption, ROS accumulation, mitochondrial dysfunction, and cancer-cell death.
2. STAT3-centered survival signaling inhibition, including ↓ STAT3 phosphorylation/transcriptional activity and, in some models, ↓ LIFR/STAT3 signaling.
3. Mitochondrial ROS and stress signaling → p38/JNK activation, mitochondrial membrane-potential loss, apoptosis, mitophagy, or paraptosis-like death depending on tumor model.
4. ↓ c-Myc with associated ↓ AKT/ERK/STAT3 signaling and inhibition of proliferative transcriptional programs.
5. Microtubule network disruption with G2/M cell-cycle disturbance.
6. DNA damage → PARP1 hyperactivation → PAR accumulation → AIF mitochondrial-to-nuclear translocation and parthanatos in multiple myeloma.
7. Intrinsic and extrinsic apoptosis signaling with ↑ Bax and caspase-3/-8/-9 and ↓ Bcl-2 in responsive cancer cells.
8. ER-stress/autophagy modulation; autophagy can be cytotoxic through PINK1/Parkin-mediated mitophagy or cytoprotective through p62/Keap1/NRF2 depending on cancer type.
9. Secondary anti-inflammatory signaling including NF-κB/TNF-α suppression, more strongly established outside direct cancer-treatment models.

Bioavailability / PK relevance: Human pharmacokinetics, metabolism, plasma exposure, oral bioavailability, tissue distribution, and a validated therapeutic exposure range for purified cynaropicrin have not been adequately established. Its electrophilic Michael-acceptor chemistry may produce rapid reaction with glutathione and protein thiols, potentially limiting free systemic exposure while also contributing to pharmacodynamic activity. Artichoke-leaf supplementation cannot be assumed to reproduce pharmacologic exposure to purified cynaropicrin.

In-vitro vs systemic exposure relevance: Most anticancer experiments use low-micromolar concentrations, commonly approximately 1–10 µM depending on model, with some activity near 1–2 µM. Whether these concentrations are achievable and sustainable in human tumors after oral or systemic administration is unknown because dedicated human cynaropicrin PK data are lacking. Therefore, concentrations effective in vitro should not presently be considered clinically exposure-validated.

Clinical evidence status: Preclinical. Anticancer evidence includes numerous cell-line studies plus xenograft mouse and zebrafish tumor models, but no established human anticancer efficacy and no validated therapeutic dosing regimen for purified cynaropicrin. Human studies of artichoke preparations for metabolic or gastrointestinal indications do not establish cancer efficacy or the PK/safety profile of purified cynaropicrin.

Cynaropicrin Cancer-Relevant Mechanisms

P: 0–30 min    R: 30 min–3 hr    G: >3 hr